3,4-dihydro-2(1H)-quinolinone is a heterocyclic compound that has been investigated for its potential pharmacological properties. It has been synthesized through various methods, including the reduction of 2-quinolinone and the cyclization of β-amino-β-arylpropionic acids. Studies have explored its effects on various biological targets, including its anti-inflammatory, antioxidant, and anticancer activities. Its importance lies in its potential therapeutic applications, and research efforts are focused on understanding its mechanisms of action and developing new drug candidates based on its structure. '
3,4-dihydro-2(1H)-quinolinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 64796 |
| CHEMBL ID | 388582 |
| CHEBI ID | 194726 |
| SCHEMBL ID | 10032 |
| MeSH ID | M000601245 |
| Synonym |
|---|
| AC-3329 |
| EN300-18580 |
| 3,4-dihydro-(1h)-quinolin-2-one |
| o-aminohydrocinnamic acid lactam |
| 3,4-dihydro-2-quinolinol |
| hydrocarbostyril |
| nsc49170 |
| nsc-49170 |
| 2(1h)-quinolinone,4-dihydro- |
| 3,4-dihydrocarbostyril |
| 553-03-7 |
| carbostyril,4-dihydro- |
| 2-oxo-1,3,4-tetrahydroquinoline |
| inchi=1/c9h9no/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-4h,5-6h2,(h,10,11 |
| 3,4-dihydro-2(1h)-quinolinone, 98% |
| smr000384280 |
| MLS001006274 |
| 3,4-dihydro-2(1h)-quinolinone |
| dihydro-quinolinone |
| CHEMBL388582 , |
| 3,4-dihydroquinolin-2(1h)-one |
| bdbm50209771 |
| HMS1729B08 |
| 3,4-dihydro-1h-quinolin-2-one |
| CHEBI:194726 |
| AKOS000121296 |
| A8009 |
| NCGC00246178-01 |
| HMS2742J17 |
| 2(1h)-quinolinone,3,4-dihydro- |
| 2-oxo-1,2,3,4-tetrahydroquinoline |
| 2(1h)-quinolinone, 3,4-dihydro- |
| carbostyril, 3,4-dihydro- (van) |
| nsc 49170 |
| unii-2ckg6tx32f |
| 2ckg6tx32f , |
| 1,2,3,4-tetrahydroquinolin-2-one |
| FT-0606200 |
| GF-0123 |
| AM20060457 |
| 3,4-dihydro-2-quinolinone |
| 1,2,3,4-tetrahydro-2(1h)-quinolinone |
| 3,4-dihydro-2(1h)-quinolone |
| 1,2,3,4-tetrahydro-2-oxoquinoline |
| hydrocarbostyril [mi] |
| 3,4-dihydro-2-quinolone |
| 3,4-dihydro-2(1h)quinolinone |
| SCHEMBL10032 |
| 3,4-dihydroquinolin-2-one |
| 3,4-dihydro-quinolin-2-one |
| 3,4 dihydroquinolin-2-(1h)-one |
| 1,2,3,4-tetrahydro-quinolin-2-one |
| 3,4-dihydro-2 (1h)quinolinone |
| 3,4-dihydroquinolin-2 (1h)-one |
| 3,4-dihydroquinolin-2-(1h)-one |
| carbostyril, 3,4-dihydro- |
| STR08974 |
| DTXSID40203816 |
| J-511198 |
| F2189-0209 |
| CS-W002108 |
| mfcd00016722 |
| Z85917566 |
| dihydroquinolinone |
| Q27254560 |
| Class | Description |
|---|---|
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.0000 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | IC50 (µMol) | 0.0007 | 0.0007 | 0.4595 | 6.3000 | AID286353 |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | IC50 (µMol) | 0.0007 | 0.0007 | 0.4728 | 6.3000 | AID286353 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | IC50 (µMol) | 0.0007 | 0.0007 | 0.4754 | 6.3000 | AID286353 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 (µMol) | 0.0007 | 0.0001 | 0.7266 | 7.8000 | AID286353; AID462319 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID286353 | Inhibition of mitogen-activated protein kinase p38 at 2 uM ATP | 2007 | Journal of medicinal chemistry, May-03, Volume: 50, Issue:9 | Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors. |
| AID462319 | Inhibition of human MAPK p38alpha | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (10.53%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (89.47%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||